|
|
Treatment Algorithm: HIV 4th Edition - Current Treatment Strategies and Commercial ImperativesPublished by: Datamonitor Published: Nov. 14, 2002 - 224 Pages Table of ContentsOverview Introduction The HIV market remains relatively immature, with only 17 HIV-specific marketed products available. The treatment of HIV is becoming increasingly complex to manage and control and HIV-infected individuals are placing much more emphasis on side effect profiles of drugs and pill burden. This analysis identifies current treatment regimens used in the 7 major markets, and highlights areas of unmet need, together with detailed epidemiological data for HIV and AIDs. Scope Based on interviews with over 300 practicing physicians in the 7 major markets: the US, Japan, Germany, France, Italy, Spain and the UK Key epidemiological and treatment data for the 7 leading country markets In-depth analysis of all the currently marketed HIV drugs, the NRTIs, NNRTIs and PIs, as well as an analysis of key pipeline drugs Case studies covering the key market players including, GlaxoSmithKline, Bristol-Myers Squibb, Abbott and Roche Report Highlights Incidence of heterosexual infections in the US will increase by 60% in the next five years, with a concurrent stabilization of incidence of HIV in homosexual individuals. Resistance testing and the increased use of structured treatment interruptions (STIs) will dominate the HIV market in the next five years Given that there are only two key marketed NNRTIs and that NNRTI-containing regimens are now recommended for first line patients, a significant opportunity exists for new market entrants in this class. Reasons to Purchase Understand how the evolution of therapeutic regimens will drive changes in HIV drug development Recognize the impact of regional variations in patient demographics on marketing strategies Evaluate key areas of unmet need in HIV therapy, and prioritize currently untreated and newly emerging segments of the patient population Identify market entry opportunities for NNRTIs in 1st-line therapy Scope Treatment trees, providing a summary of the main epidemiological and treatment data DRIVERS AND TRENDS The HIV market remains relatively immature, with only 17 HIV-specific marketed products supplying the global HIV-treated population. The treatment of HIV is becoming increasingly complex to manage and control, and HIV-infected individuals are placing much more emphasis on side effect profiles of drugs and pill burden. PATIENT POTENTIAL Review of the clinical aspects of HIV infection and AIDS indicator symptoms, with overall prevalence data for HIV/AIDS in the seven major markets Clinical manifestation of HIV/AIDS Overall prevalence of HIV/AIDS DIAGNOSIS In-depth segmentation of the HIV/AIDS-diagnosed population by mode of transmission, age/gender and race/ethnicity in the US. How is the HIV population segmented across the seven major markets? What are the reasons behind differences in segmentation? Which niches should companies target? DRUG THERAPY OVERVIEW Drug use is segmented by line of therapy, drug class and individual drug across the seven major markets. How is the HIV treated patient population segmented by line of therapy? How is the segmentation of patients by line of therapy going to change? How are currently marketed drugs used in niche patient populations? How long are patients maintained in each line of therapy on average? COMMERCIAL STRATEGIES Analysis of the key company strategies used in the HIV sector and how these companies have profited from implementing them. What should new players to this sector be aiming for? How can current players increase profitability? What are the key unmet needs in this market? APPENDIX Drug usage tables and treatment trees provided from primary research. DATASETS Table 1: Prevalence and diagnosis and treated HIV/AIDS populations in the seven major markets, 2002 Table 2: Adult male HIV diagnosed population by mode of transmission, 2002 Table 3: First line HIV therapy patient share (%), 2002 Table 4: Symptoms associated with acute HIV infection Table 5: AIDS case definitions Table 6: AIDS indicator conditions Table 7: Table showing HIV and AIDS diagnosed population Table 8: Forecast of estimated prevalence of HIV/AIDS in the seven major markets (000’s), 2003-2010 Table 9: Prevalence, diagnosis and treated HIV/AIDS populations in the seven major markets, 2002 Table 10: HIV diagnosed population by age, 2002 Table 11: HIV diagnosed population by gender, 2002 Table 12: AIDS diagnosed population by age, 2002 Table 13: AIDS diagnosed population by gender, 2002 Table 14: Male HIV diagnosed population across seven major markets, 2002 Table 15: Female HIV diagnosed population across seven major markets, 2002 Table 16: Male AIDS diagnosed population across seven markets, 2002 Table 17: Female AIDS diagnosed population across seven markets, 2002 Table 18: Adult male HIV diagnosed population by mode of transmission, 2002 Table 19: Adult female HIV diagnosed population by mode of transmission, 2002 Table 20: Pediatric male HIV diagnosed pediatric population by mode of transmission, 2002 Table 21: Pediatric female HIV diagnosed pediatric population by mode of transmission, 2002 Table 22: Adult male AIDS diagnosed population by mode of transmission, 2002 Table 23: Adult female AIDS diagnosed population by mode of transmission, 2002 Table 24: Male pediatric AIDS diagnosed population by mode of transmission, 2002 Table 25: Female pediatric AIDS diagnosed population by mode of transmission, 2002 Table 26: Adult male HIV diagnosed population, by race/ethnicity in the US, 2002 Table 27: Adult female HIV diagnosed population, by race/ethnicity in the US, 2002 Table 28: Pediatric male HIV diagnosed population, by race/ethnicity in the US, 2002 Table 29: Pediatric female HIV diagnosed population, by race/ethnicity in the US, 2002 Table 30: Adult male AIDS diagnosed population, by race/ethnicity in the US, 2002 Table 31: Adult female AIDS diagnosed population, by race/ethnicity in the US, 2002 Table 32: Pediatric male AIDS diagnosed population, by race/ethnicity in the US, 2002 Table 33: Pediatric female AIDS diagnosed population, by race/ethnicity in the US, 2002 Table 34: Adult infectious co-morbidities for the HIV/AIDS population, 2002 Table 35: Adult non-infectious co-morbidities for the HIV/AIDS population, 2002 Table 36: HIV treated patients across the seven major markets, 2002 Table 37: Segmentation of compliant treated patients by line of therapy, 2002 Table 38: Average number of drugs prescribed per patient by line of therapy, 2002 Table 39: Comparison of physician prescribing patterns by rank Table 40: Average number of drugs prescribed for the NRTIs by line of therapy Table 41: Average number of drugs prescribed for the NNRTIs by line of therapy, 2002 Table 42: Average number of drugs prescribed for the PIs by line of therapy, 2002 Table 43: First line regimen patient share (%), 2002 Table 44: Second line regimen patient share (%), 2002 Table 45: Third line regimen patient share (%), 2002 Table 46: Salvage regimen patient share (%), 2002 Table 47: Overall drug usage (%) for all lines of therapy Table 48: Overall drug use (%) in 1st line therapy Table 49: Overall drug usage (%) in 2nd line therapy Table 50: Overall drug use (%) in 3rd line therapy Table 51: Overall drug use (%) in salvage therapy Table 52: Average length of patient time (months) in each line of therapy Table 53: Drug class patient share (%) in first line therapy Table 54: Drug class patient share (%) in second line therapy Table 55: Drug class patient share (%) in third line therapy Table 56: Drug class patient share (%) in salvage therapy Table 57: Overall patient share across all lines of therapy Table 58: Patient share (%) for the NRTIs in first line therapy Table 59: Patient share (%) for the NNRTIs in first line therapy Table 60: Patient share (%) for the PIs in first line therapy Table 61: Patient share (%) for the NRTIs in second line therapy Table 62: Patient share (%) for the NNRTIs in second line therapy Table 63: Patient share (%) for the PIs in second line therapy Table 64: Patient share (%) for the NRTIs in third line therapy Table 65: Patient share (%) for the NNRTIs in third line therapy Table 66: Patient share (%) for the PIs in third line therapy Table 67: Patient share (%) for the NRTIs in salvage therapy Table 68: Patient share (%) for the NNRTIs in salvage therapy Table 69: Patient share (%) for the PIs in salvage therapy Table 70: NRTI drug use (%) for 2 NRTI + 1 PI regimen in first line therapy Table 71: PI drug use (%) for 2 NRTI + 1 PI regimen in first line therapy Table 72: NRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in first line therapy Table 73: NNRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in first line therapy Table 74: NRTI drug use (%) for 3 NRTI regimen in first line therapy Table 75: NRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in first line therapy Table 76: NNRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in first line therapy Table 77: PI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in first line therapy Table 78: NRTI drug use (%) for 3 NRTI + 1 PI regimen in first line therapy Table 79: PI drug use (%) for 3 NRTI + 1 PI regimen in first line therapy Table 80: NRTI drug use (%) for 2 NRTI + 2 PI regimen in first line therapy Table 81: PI drug use (%) for 2 NRTI + 2 PI regimen in first line therapy Table 82: NRTI drug use (%) for 2 NRTI + 1 PI regimen in second line therapy Table 83: PI drug use (%) for 2 NRTI + 1 PI regimen in second line therapy Table 84: NRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in second line therapy Table 85: NNRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in second line therapy Table 86: NRTI drug use (%) for 3 NRTI regimen in second line therapy Table 87: NRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in second line therapy Table 88: NNRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in second line therapy Table 89: PI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in second line therapy Table 90: NRTI drug use (%) for 3 NRTI + 1 PI regimen in second line therapy Table 91: PI drug use (%) for 3 NRTI + 1 PI regimen in second line therapy Table 92: NRTI drug use (%) for 2 NRTI + 2 PI regimen in second line therapy Table 93: PI drug use (%) for 2 NRTI + 2 PI regimen in second line therapy Table 94: NRTI drug use (%) for 2 NRTI + 1 PI regimen in third line therapy Table 95: PI drug use (%) for 2 NRTI + 1 PI regimen in third line therapy Table 96: NRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in third line therapy Table 97: NNRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in third line therapy Table 98: NRTI drug use (%) for 3 NRTI regimen in third line therapy Table 99: NRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in third line therapy Table 100: NNRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in third line therapy Table 101: PI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in third line therapy Table 102: NRTI drug use (%) for 3 NRTI + 1 PI regimen in third line therapy Table 103: PI drug use (%) for 3 NRTI + 1 PI regimen in third line therapy Table 104: NRTI drug use (%) for 2 NRTI + 2 PI regimen in third line therapy Table 105: PI drug use (%) for 2 NRTI + 2 PI regimen in third line therapy Table 106: NRTI drug use (%) for 2 NRTI + 1 NNRTI + 1 PI regimen in third line therapy Table 107: NNRTI drug use (%) for 2 NRTI + 1 NNRTI + 1 PI regimen in third line therapy Table 108: PI drug use (%) for 2 NRTI + 1 NNRTI + 1 PI regimen in third line therapy Table 109: NRTI drug use (%) for 1 NRTI + 2 PI regimen in third line therapy Table 110: PI drug use (%) for 1 NRTI + 2 PI regimen in third line therapy Table 111: NRTI drug use (%) for 2 NRTI + 1 NNRTI + 2 PI regimen in third line therapy Table 112: NNRTI drug use (%) for 2 NRTI + 1 NNRTI + 2 PI regimen in third line therapy Table 113: PI drug use (%) for 2 NRTI + 1 NNRTI + 2 PI regimen in third line therapy Table 114: NRTI drug use (%) for 2 NRTI + 1 PI regimen in salvage therapy Table 115: PI drug use (%) for 2 NRTI + 1 PI regimen in salvage therapy Table 116: NRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in salvage therapy Table 117: NNRTI drug use (%) for 2 NRTI + 1 NNRTI regimen in salvage therapy Table 118: NRTI drug use (%) for 3 NRTI regimen in salvage therapy Table 119: NRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in salvage therapy Table 120: NNRTI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in salvage therapy Table 121: PI drug use (%) for 1 NRTI + 1 NNRTI + 1 PI regimen in salvage therapy Table 122: NRTI drug use (%) for 3 NRTI + 1 PI regimen in salvage therapy Table 123: PI drug use (%) for 3 NRTI + 1 PI regimen in salvage therapy Table 124: NRTI drug use (%) for 2 NRTI + 2 PI regimen in salvage therapy Table 125: PI drug use (%) for 2 NRTI + 2 PI regimen in salvage therapy Table 126: NRTI drug use (%) for 3 NRTI + 2 PI regimen in salvage therapy Table 127: PI drug use (%) for 3 NRTI + 2 PI regimen in salvage therapy Table 128: NRTI drug use (%) for 2 NRTI + 1 NNRTI + 2 PI regimen in salvage therapy Table 129: NNRTI drug use (%) for 2 NRTI + 1 NNRTI + 2 PI regimen in salvage therapy Table 130: PI drug use (%) for 2 NRTI + 1 NNRTI + 2 PI regimen in salvage therapy Table 131: NRTI drug use (%) for 1 NRTI + 2 PI regimen in salvage therapy Table 132: PI drug use (%) for 1 NRTI + 2 PI regimen in salvage therapy AbstractThe HIV market remains relatively immature, with only 17 HIV-specific marketed products available. The treatment of HIV is becoming increasingly complex to manage and control and HIV-infected individuals are placing much more emphasis on side effect profiles of drugs and pill burden. This analysis identifies current treatment regimens used in the 7 major markets, and highlights areas of unmet need, together with detailed epidemiological data for HIV and AIDs.Based on interviews with over 300 practicing physicians in the 7 major markets: the US, Japan, Germany, France, Italy, Spain and the UKKey epidemiological and treatment data for the 7 leading country marketsIn-depth analysis of all the currently marketed HIV drugs, the NRTIs, NNRTIs and PIs, as well as an analysis of key pipeline drugsCase studies covering the key market players including, GlaxoSmithKline, Bristol-Myers Squibb, Abbott and RocheTreatment trees, providing a summary of the main epidemiological and treatment dataIncidence of heterosexual infections in the US will increase by 60% in the next five years, with a concurrent stabilization of incidence of HIV in homosexual individuals.Resistance testing and the increased use of structured treatment interruptions (STIs) will dominate the HIV market in the next five yearsGiven that there are only two key marketed NNRTIs and that NNRTI-containing regimens are now recommended for first line patients, a significant opportunity exists for new market entrants in this class.Understand how the evolution of therapeutic regimens will drive changes in HIV drug developmentRecognize the impact of regional variations in patient demographics on marketing strategiesEvaluate key areas of unmet need in HIV therapy, and prioritize currently untreated and newly emerging segments of the patient populationIdentify market entry opportunities for NNRTIs in 1st-line therapyGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||